When more time becomes a research program
There’s something very understandable about wanting more time. More dinners with people we love, more chances to finish the thing we keep postponing, more years in a body that lets us enjoy being here. Then Silicon Valley enters the conversation, and suddenly the wish comes with a laboratory, a funding round and the possibility that someone will eventually ask us to update the firmware on our existential crisis.
The science behind this ambition deserves a careful look. Researchers are studying cellular rejuvenation, brain-computer interfaces and ways of preserving biological tissue. Each field has meaningful questions and measurable results. Around those results sits a much larger story about immortality, identity and whether a person could someday continue inside a machine. I find both stories interesting, provided we keep track of where an experiment ends and an imagined future begins.
As of this October 20, 2026 update, there’s no demonstrated technology that uploads a person’s consciousness or revives someone from long-term cryonic preservation. Research into age-related disease has made real progress, including early clinical work. Those facts can share a paragraph. We can appreciate a promising experiment without asking it to carry the entire weight of our fear of death, which is a substantial assignment for any laboratory.
What cellular reprogramming actually means
The foundation is extraordinary enough on its own. The 2012 Nobel Prize in Physiology or Medicine recognized John Gurdon and Shinya Yamanaka for discoveries showing that mature cells can be reprogrammed to a pluripotent state. Such cells can give rise to many cell types. That changed how researchers study development and disease. It didn’t establish a way to turn an entire adult body back to a preferred birthday, complete with the knees we remember having then.
Full reprogramming changes cellular identity, which creates an obvious challenge for rejuvenation: a useful cell still needs to perform its job. Partial reprogramming explores whether some age-associated features can be altered while retaining that function. Control over the intervention matters enormously, including which cells receive it and for how long. The goal of preserving useful function is very different from simply pushing every cell toward a more flexible developmental state.
A 2020 Nature study illustrates the promise and the boundaries. Researchers expressed three reprogramming factors, known as OSK, in mouse retinal ganglion cells and reported improvements in regeneration and visual function in particular experimental models. That’s a result in mice, in a specific tissue, under defined conditions. Translating it into a treatment for patients requires its own evidence. Translating it into a claim that people can already reverse whole-body aging requires a leap the study never made.
An important 2026 update, with a very small denominator
Life Biosciences’ ER-100 program has now taken this approach into an early clinical trial for optic neuropathies. The registered study, NCT07290244, is designed to evaluate safety and tolerability. In June 2026, the company announced that its first participant had been dosed. That is a meaningful transition from preclinical research to testing in people, while remaining a long way from a proven treatment or an intervention shown to extend lifespan.
On October 8, 2026, the company reported interim observations in three participants with open-angle glaucoma. It said treatment was well tolerated through Day 56 and described preliminary visual-field improvements in two participants. These are company-reported findings from an ongoing Phase 1 trial, with a tiny sample and short follow-up. They deserve attention at that scale, rather than promotion into proof that aging has been reversed across the body.
I’m interested in what the next stages will establish: whether effects persist, how safety looks with more participants and follow-up, and whether later studies demonstrate a meaningful benefit. The clinical question is valuable in its own right. Helping someone retain or regain useful vision would matter enormously, even if the result never turns into a birthday candle shortage. A specific medical benefit can be impressive without receiving an immortality costume.
The money is real; the outcome still needs testing
Altos Labs publicly launched on January 19, 2022, announcing $3 billion in committed funding. Its stated mission concerns restoring cellular health and resilience to address disease, injury and disability. The launch announcement supplies a solid basis for discussing the scale of investment. It supplies no basis for saying that the investment has already purchased decades of extra life. Capital can support a research program; successful medicine still has to emerge from the work.
Calico offers another example of substantial institutional support for aging biology. Its own account describes a 2013 launch with Google’s backing and an effort to connect fundamental discoveries with potential medicines. The company publishes research and describes drug-development programs, making the original image of an entirely secretive operation too sweeping. Its mission is ambitious, but statements that Calico regards death as optional attribute a conclusion that its research has not demonstrated.
There’s a corporate update here as well: the Rejuveron website now redirects to Centenara Labs. The current organization describes a portfolio approach to therapies for age-related diseases and longer healthspan. That is a more accurate description than presenting it as one gene-editing treatment capable of switching aging off. The field contains many strategies, at different stages, and a company’s broad mission shouldn’t be mistaken for results from a particular therapy.
A younger-looking number needs context
The term biological age sounds reassuringly definite, as though the body carries a second birth certificate in a drawer. In practice, different tests estimate different aspects of aging from patterns in measurements. Epigenetic clocks, for example, use DNA methylation information. Their outputs can be useful in research, while their meaning depends on the clock, the sample and the question being studied. A score is a measurement produced by a model, rather than a direct count of remaining years.
In the CALERIE trial, researchers studying calorie restriction reported a change in one measure of the pace of aging without significant changes in other biological-age estimates. That difference is instructive. A single intervention can produce different answers from different tools. A shift in a biomarker also needs to be connected to outcomes that matter to patients, such as function, disease and survival. The relationship has to be studied rather than supplied by an appealing before-and-after graphic.
I’d read a longevity claim by asking what was measured and in whom. Was the result in a dish, an animal, a small trial or a larger controlled study? Was the endpoint a laboratory marker or a health outcome? How long did observation continue? Those questions let the promising work stand on its own merits. A lower number can be worth investigating without becoming permission to order a cake with thirty fewer candles.
Neuralink connects signals to devices
Neuralink belongs in a conversation about neurotechnology, with a clear description of its clinical purpose. Its PRIME study concerns an investigational implantable brain-computer interface for people with quadriplegia. The company has reported participants using recorded brain signals to control external devices, including a computer cursor. That can offer valuable independence. It is an accomplishment involving signals and control, rather than the transfer of an entire mind into computer storage.
A decoder trained to recognize movement intention is solving a particular problem. Memories, personality and an ongoing subjective point of view raise much broader problems. A useful interface doesn’t demonstrate that all of those can be extracted, copied or restored elsewhere. My original article blurred that boundary, and the distinction matters. The people participating in medical research deserve to have their achievements described accurately, rather than turned into supporting characters in a story about digital eternity.
There are also different meanings of a digital version of a person. An AI system trained on someone’s writing or recordings might imitate aspects of how they speak. That imitation alone supplies no evidence that their awareness has continued inside it. A familiar sentence can be emotionally powerful while the question of consciousness remains unresolved. I’d want that difference made clear to anyone being invited to trust a product with a loved one’s memory.
Cryonics preserves a possibility, with revival unproven
Cryonics organizations arrange preservation after legal death in the hope that future technologies might make revival possible. The Cryonics Institute specializes in whole-body preservation; its FAQ explicitly says it doesn’t offer the separate brain-only option. That corrects my earlier description. The same FAQ acknowledges that a whole mammal has not been cryopreserved to cryogenic temperatures and revived. The proposed future remains the reason people choose the service, rather than an outcome the service has achieved.
Cryoprotective chemicals and controlled cooling aim to limit damage, including ice formation. The wider science of cryopreservation has produced important results at smaller scales. A 2023 Nature Communications study reported vitrification, nanowarming and life-sustaining transplantation of rat kidneys after storage. That’s significant organ-preservation research. Recovering the function of a rat kidney and reviving an entire person after long-term storage are substantially different tasks, and the first result doesn’t establish the second.
The distinction lets us take both the research and the uncertainty seriously. A stored body would need far more than warming: the original cause of death and preservation-related injuries would also need to be addressed, alongside questions about brain function. Long-term preservation also depends on institutions, resources and care continuing over time. I can understand the wish to leave a door open while recognizing that nobody can provide a reliable arrival date for the imagined rescue team.
A preserved brain is still a long way from a preserved self
Nectome’s current website describes post-mortem whole-body preservation intended to retain fine brain structure and make future revival theoretically possible. It frames revival as a hope. That current description replaces my earlier, overly categorical account of its process as a procedure offered to end someone’s life. The central evidence question remains what has been preserved and what that preservation can eventually support. A company’s confidence in a future possibility is different from a demonstration of that possibility.
A connectome maps connections among neurons. Those maps are remarkable scientific achievements, but a structural map and a functioning mind aren’t interchangeable descriptions. Researchers published a major adult fruit-fly brain wiring resource in 2024, showing how much detailed work is involved even at that scale. Understanding how a network operates requires further research. Preserving visible structure by itself doesn’t demonstrate that all information needed for memory, personality and conscious experience has survived.
Even a future machine that behaved convincingly like a particular person would leave a philosophical question: what would establish continuity of their experience? A copy might claim to be the original; that claim would not settle the issue for everyone. I find the question fascinating because it exposes how much we mean by the word me. It includes remembered facts, relationships, bodily experience and the peculiar certainty of being the one living through this particular afternoon.
Who benefits from the extra years we hope to create?
The presence of wealthy founders and substantial private investment raises a fair question about access. If a useful therapy emerges, who will receive it, and under what conditions? Research funding, trial participation, pricing and distribution can all shape the eventual answer. Those are decisions worth discussing while treatments are being developed. We don’t need to assume that billionaires have already acquired a guaranteed second century in order to care about how future benefits might be shared.
I’m also interested in what gets counted as success. A treatment that preserves sight, helps someone remain independent or reduces the burden of an age-related disease could add enormous value to ordinary life. More years become especially meaningful when people have the support to enjoy them. Housing, care, companionship and accessible medicine belong in that picture. It would be a peculiar triumph to extend the calendar while making everyday existence harder to afford.
The legal questions around hypothetical uploads are interesting, too, but they remain hypothetical in this context. We can consider consent, identity and responsibility without pretending that a preserved consciousness is already sending legally recognized instructions from a server. Any eventual rules would depend on real systems and specific jurisdictions. Philosophy gives us room to explore the scenario; reporting needs to keep the scenario labeled. Even an imaginary digital afterlife deserves better than a confident prediction about its paperwork.
What I’d actually want from more time
I’d definately welcome research that helps people remain well enough to do the things that make their lives feel like their own. That desire seems both modest and enormous: another walk, another conversation, another dinner where nobody is watching the clock. It’s also a useful way to evaluate the field. Which studies bring a tangible benefit closer, and which claims are mostly offering a dramatic story about the future? Both can attract attention, but they ask for different kinds of trust.
Cellular reprogramming also differs from CRISPR editing: changing gene activity and changing a DNA sequence are distinct approaches, even when a treatment uses genetic delivery tools. That sort of distinction can sound technical until an entire promise depends on it. I’d rather understand the mechanism and its limits than let a collection of impressive terms persuade me that every problem of aging has become one software update away from resolution.
The most compelling version of this story gives serious science the space to be unfinished. A promising clinical observation can lead to a better study; a preservation method can teach us about tissue; a brain interface can make a practical difference today. We can follow all of that with curiosity and a little humility. More time would be wonderful. In the meantime, I’d like the evidence to arrive before the invitation to my 150th birthday party.
Related Reads
The Science of Decomposition: What Really Happens When We Die
Plants Can Sense the Dead? What Science Says About Flora and Human Remains
Run Toward Time: How 75 Minutes a Week Can Reverse 12 Years of Biological Aging
Inside Elon Musk’s Mind: Neuralink, Brain Chips, and the Billion-Dollar Question
Sources
Nature — OSK reprogramming and visual function in mice, 2020
Life Biosciences — company-reported interim data in three participants, October 8, 2026
Altos Labs — launch announcement and committed funding, January 19, 2022
Nature Aging — CALERIE randomized-trial analysis of DNA methylation measures
Cryonics Institute — FAQ, whole-body service and unproven revival
Nature Communications — vitrification, nanowarming and rat kidney transplantation, 2023
Nature — neuronal wiring diagram of an adult fly brain, 2024
Updated October 20, 2026. Images are AI-generated editorial concepts, not photographs of research results, medical devices or preservation facilities. The title’s reference to a soul is a philosophical metaphor.
